| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | AZD0530 | CTRPv2 | pan-cancer | AAC | -0.0042 | 0.9 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.0038 | 0.9 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0037 | 0.9 |
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | -0.0059 | 0.9 |
| mRNA | BRD-K41334119 | CTRPv2 | pan-cancer | AAC | -0.0081 | 0.9 |
| mRNA | Mitomycin-C | GDSC1000 | pan-cancer | AAC | 0.0039 | 0.9 |
| mRNA | BRD-K86535717 | CTRPv2 | pan-cancer | AAC | -0.0079 | 0.9 |
| mRNA | BRD-K13999467 | CTRPv2 | pan-cancer | AAC | -0.0039 | 0.9 |
| mRNA | tandutinib | CTRPv2 | pan-cancer | AAC | -0.0037 | 0.9 |
| mRNA | Bortezomib | GDSC1000 | pan-cancer | AAC | 0.005 | 0.9 |